Study Explores Modified AAV Variants to Enhance Gene Delivery in Human Vascular Endothelial Cells

A study published in the journal *Gene Therapy* examines advancements in adeno-associated virus (AAV) variants designed to improve transduction efficiency in human vascular endothelial cells. Researchers, led by Stamataki et al., focused on refining these viral vectors, which are widely used in gene therapy applications targeting blood vessel cells. The findings highlight modifications to AAV variants that enhance their ability to deliver genetic material into these specific cell types.

The research addresses a critical challenge in gene therapy: optimizing delivery systems for therapeutic genes. Human vascular endothelial cells play a key role in various physiological processes and are often targeted for treating cardiovascular diseases and other conditions. The study explores how engineered AAV variants can overcome barriers to efficient transduction, potentially improving outcomes for therapies aimed at these cells. The researchers detail the methods used to modify the viral vectors and report significant improvements in their ability to interact with and enter human vessel cells.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

For any suggestion and feedback, please contact us.

Date: November 15, 2025

Author

GOAI